Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/14202
Nаziv: | Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor | Аutоri: | Bianco M. D'ascenzo F. Raposeiras Roubin S. Kinnaird T. Peyracchia M. Ariza-Solé A. Cerrato E. Manzano-Fernández S. Gravinese C. Templin C. Destefanis P. Lazar Velicki Luciano A. Xanthopoulou I. Rinaldi M. Rognoni A. Varbella F. Boccuzzi G. Omedè P. Montabone A. Bernardi A. Taha S. Rossini R. Durante A. Gili S. Magnani G. Autelli M. Grosso A. Blanco P. Giustetto C. Garay A. Quadri G. Queija B. Ilija Srdanović Paz R. Fernández M. Pousa I. Gallo D. Morbiducci U. Dominguez-Rodriguez A. Lopez-Cuenca Á. Cequier A. Alexopoulos D. Iñiguez-Romo A. Pozzi R. Assi E. Valgimigli M. |
Ključnе rеči: | DAPT;Prasugrel;Ticagrelor;Bleeding;PRECISE DAPT;PARIS risk score | Dаtum izdаvаnjа: | 1-јан-2019 | Čаsоpis: | International Journal of Cardiology | Sažetak: | © 2019 Elsevier B.V. Background: The PRECISE-DAPT and PARIS risk scores (RSs) were recently developed to help clinicians at individualizing the optimal dual antiplatelet therapy duration (DAPT) after percutaneous coronary intervention (PCI). Nevertheless, external validation of these RSs it has not yet been performed in ACS (acute coronary syndrome) patients treated with prasugrel or ticagrelor in a real- world scenario. Methods: 4424 ACS patients who underwent PCI and survived to hospital discharge, from January 2012 to December 2016 at 12 European centers, were included. PRECISE-DAPT and PARIS bleeding RS, as well as PARIS ischemic RS, were computed, and their performance at predicting major bleeding (MB; BARC type 3 or 5) and ischemic events (MI and stent thrombosis) during follow up was compared. Results: After a median follow-up of 14 (interquartile range 12–20.9) months, 83 (1.88%) patients developed MB and 133 (3.0%) suffered an ischemic episode. PRECISE-DAPT performed better than PARIS bleeding RS (c-statistic = 0.653 vs. 0.593; p =.01 for comparison) in predicting MB. The RSs performance for MB prediction remained consistent in STEMI patients (c-statistic = 0.632 vs 0.575) or in those treated with prasugrel (c-statistic = 0.623 vs 0.586). PARIS ischemic RS exhibited superior discrimination in predicting ischemic complications compared to PRECISE-DAPT (c-statistic = 0.604 vs 0.568 p =.05 for comparison). Conclusion: Our data provide support to the use of PRECISE-DAPT in MB risk stratification for patients receiving DAPT in form of aspirin and prasugrel or ticagrelor whereas the PARIS ischemic RS has potential to complement the risk prediction with respect to ischemic events. | URI: | https://open.uns.ac.rs/handle/123456789/14202 | ISSN: | 1675273 | DOI: | 10.1016/j.ijcard.2019.11.132 |
Nаlаzi sе u kоlеkciјаmа: | MDF Publikacije/Publications |
Prikаzаti cеlоkupаn zаpis stаvki
SCOPUSTM
Nаvоđеnjа
22
prоvеrеnо 29.04.2023.
Prеglеd/i stаnicа
44
Prоtеklа nеdеljа
12
12
Prоtеkli mеsеc
0
0
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.